Epstein-Barr virus latent membrane protein 1 and 2 peptides presented by major histocompatibility complex class I (EBV LMP1/LMP2-MHC I)

Epstein-Barr virus (EBV) latent membrane proteins 1 and 2 (LMP1 and LMP2) are oncogenic viral proteins expressed during the latency II and III phases of EBV infection, which are associated with various malignancies such as nasopharyngeal carcinoma and Hodgkin lymphoma (PMID: 11248601, 15141011). These proteins are processed by the host cell's proteasome into short peptides that are subsequently loaded onto major histocompatibility complex (MHC) class I molecules and presented on the cell surface (PMID: 10438931). This peptide-MHC (pMHC) complex serves as a highly specific target for the cellular immune system, particularly CD8+ cytotoxic T-lymphocytes (CTLs). Therapeutic strategies targeting these complexes include adoptive T-cell therapies, such as Tabelecleucel (Ebvallo), and TCR-engineered cells designed to recognize specific viral epitopes like the LMP2-derived CLGGLLTMV peptide (PMID: 36543163). Because LMP1 and LMP2 are viral proteins not typically expressed in healthy human tissues, they represent ideal targets for precision immunotherapy to eliminate EBV-transformed cells while minimizing damage to normal tissue. However, the efficacy of these treatments is often restricted by the patient's specific HLA genotype, as the peptides must be presented by compatible MHC molecules to be recognized by therapeutic T cells (PMID: 29109440).

Other names

EBV LMP1/2 pMHCLMP1/LMP2-HLA complexEpstein-Barr virus latent membrane protein antigensEBV-specific peptide-MHC complexesLMP1/2-MHC class I complex

Targeting of EBV-infected cells via T-cell receptor (TCR) recognition of viral peptides presented on MHC class I, leading to cytotoxic T-lymphocyte (CTL) mediated lysis.